- Home
- ANAB vs CVAC Comparison
ANAB vs CVAC Comparison
Compare ANAB & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CVAC
- Stock Information
- Founded
- ANAB 2005
- CVAC 2000
- Country
- ANAB United States
- CVAC Germany
- Employees
- ANAB N/A
- CVAC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ANAB Health Care
- CVAC Health Care
- Exchange
- ANAB Nasdaq
- CVAC Nasdaq
- Market Cap
- ANAB 759.5M
- CVAC 818.8M
- IPO Year
- ANAB 2017
- CVAC 2020
- Fundamental
- Price
- ANAB $20.55
- CVAC $3.12
- Analyst Decision
- ANAB Buy
- CVAC Buy
- Analyst Count
- ANAB 10
- CVAC 2
- Target Price
- ANAB $36.38
- CVAC $10.00
- AVG Volume (30 Days)
- ANAB 1.0M
- CVAC 717.4K
- Earning Date
- ANAB 05-08-2025
- CVAC 04-10-2025
- Dividend Yield
- ANAB N/A
- CVAC N/A
- EPS Growth
- ANAB N/A
- CVAC N/A
- EPS
- ANAB N/A
- CVAC 0.75
- Revenue
- ANAB $91,280,000.00
- CVAC $554,073,921.00
- Revenue This Year
- ANAB N/A
- CVAC N/A
- Revenue Next Year
- ANAB $37.76
- CVAC $66.34
- P/E Ratio
- ANAB N/A
- CVAC $4.19
- Revenue Growth
- ANAB 432.03
- CVAC 895.54
- 52 Week Low
- ANAB $12.21
- CVAC $2.22
- 52 Week High
- ANAB $41.31
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- ANAB 65.12
- CVAC 53.48
- Support Level
- ANAB $15.40
- CVAC $3.05
- Resistance Level
- ANAB $19.82
- CVAC $3.02
- Average True Range (ATR)
- ANAB 1.49
- CVAC 0.19
- MACD
- ANAB 0.16
- CVAC 0.06
- Stochastic Oscillator
- ANAB 96.26
- CVAC 79.14
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.